Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) investors of a class action representing investors that bought securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). Cassava investors have until February 10, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...

Financial Position - Unaudited cash and cash equivalents balance as of December 31, 2024 was approximately $128.6 million[4] Workforce Reduction - The company reduced its workforce by 10 employees, a reduction of 33%[7] - Estimated one-time costs of approximately $0.4 million related to severance payments for the workforce reduction[8] - Workforce reduction expected to be completed, and associated costs incurred, during the first quarter of 2025[8] Clinical Trials and Study Results - Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet prespecified co-primary endpoints[6] - The company decided to discontinue its Phase 3 ReFocus-ALZ study and its open-label extension study[6] - The company plans to share detailed study results at a future medical meeting[10] Forward-Looking Statements and Risks - Forward-looking statements include risks related to clinical study timelines, unexpected costs, and drug development uncertainties[11] Regulatory and Reporting - The company's press release dated January 7, 2025, is attached as Exhibit 99.1[12] - The report is signed by Eric J. Schoen, Chief Financial Officer, on January 7, 2025[15]

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a clinical-stage biotechnology company focused on developing ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=120897&from=3 CLASS PERIOD: ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/psl ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=120458&from=4 CLASS PERIOD: Februar ...

Lawsuit Overview - A securities class action lawsuit has been filed against Cassava Sciences Inc (NASDAQ: SAVA) in the United States District Court for the Western District of Texas [1] - The lawsuit is on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024 [1] - The lead plaintiff deadline is February 10, 2025 [1] Allegations Against Cassava Sciences - Defendants allegedly made materially false and/or misleading statements during the Class Period [3] - Defendants failed to disclose material adverse facts about the company's business, operations, and prospects [3] - Specifically, Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, even in mild to moderate cases [3] - As a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis [3] Lead Plaintiff Process - Cassava investors may seek to be appointed as a lead plaintiff representative of the class no later than February 10, 2025 [4] - The lead plaintiff is usually the investor or small group of investors with the largest financial interest who are also adequate and typical of the proposed class [4] - The lead plaintiff selects counsel to represent the lead plaintiff and the class [4] - Investors' ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff [4] Law Firm Information - Kessler Topaz Meltzer & Check LLP is prosecuting the class action [5] - The firm has recovered billions of dollars for victims of fraud and other corporate misconduct [5] - The firm's goal is to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries [5]

RADNOR, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/psl ...

RADNOR, Pa., Dec. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025 ...